Successful treatment with thrombopoietin receptor agonist in avoiding splenectomy for patients with chronic refractory immune thrombocytopenia.

13 A phase I/II study conducted in 2007 with 118 patients with refractory and chronic relapsing ITP demonstrated that most patients were able to maintain an elevated platelet count at higher doses of eltrombopag, and showed a trend towards fewer episodes of bleeding. 12 Again, similar positive results were yielded from a multinational phase III randomised, double-blind, placebo-controlled trial of patients with chronic ITP. 11 , 14 Following the successful introduction of TPO receptor agonists in trials where it was used as a second line treatment using different guidelines, 3 – 5 this novel therapy proved promising for the future of patients suffering from chronic refractory ITP.

also in 53,322 other papers